Noventure grants Axmer exclusive distribution right for its products Oleoabrax® EHO and EPA3G® in the Nordic and in the Baltic Countries.

Noventure grants Axmer exclusive distribution right for its products Oleoabrax® EHO and EPA3G® in Sweden, Denmark, Norway, Finland, Estonia, Latvia and Lithuania.

Oleoabrax® EHO is a hydrogel whose patented formulation grants it the ability to promote and speed up the process of healing wounds of full and partial thickness.

Oleoabrax® EHO is a class IIb medical device and complies with the Essential Requirements of Directive 93/42/EEC and subsequent amendments (CE 0476, Noventure SL).

EPA3G® is a convenient IP-protected liquid emulsion that provides a more readily bioavailable formulation of EPA. Created using our unique Emugel™ omega-3 nano-emulsion technology, EPA3G® is the only product on the market offering a high quantity of almost 3g EPA in a single 20mL dosage form, thus helping to re-establish critical levels of omega-3 EPA.

EPA3G® is a food supplement.